← Zurück zu Insidertransaktionen
Andrew Reardon
Gemeldet als: Reardon Andrew
Insider · CLO & Secretary
Käufe
0
0 USD
Verkäufe
42
7.528.203 USD
Unternehmen
1
mit gemeldeten Geschäften
Letzte Aktivität
02.11.2026
42 Transaktionen gesamt
| Datum | Unternehmen | Position | Art | Volumen | Preis | Stückzahl | Seit Meldung |
|---|---|---|---|---|---|---|---|
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 38.777,20 USD | 323,14 USD | 120 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 64.288,00 USD | 321,44 USD | 200 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 102.390,34 USD | 319,97 USD | 320 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 140.239,66 USD | 318,73 USD | 440 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 89.013,99 USD | 317,91 USD | 280 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 25.166,40 USD | 314,58 USD | 80 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 126.440,93 USD | 313,75 USD | 403 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 198.349,63 USD | 312,85 USD | 634 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 162.093,26 USD | 311,72 USD | 520 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 152.201,30 USD | 310,61 USD | 490 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 161.772,86 USD | 309,91 USD | 522 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 218.369,01 USD | 308,43 USD | 708 | – |
| 02.11.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 86.991,85 USD | 307,39 USD | 283 | – |
| 02.10.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 5.231,58 USD | 307,74 USD | 17 | – |
| 02.10.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 72.189,91 USD | 307,19 USD | 235 | – |
| 02.10.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 123.698,09 USD | 306,18 USD | 404 | – |
| 02.10.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 467.431,14 USD | 304,52 USD | 1.535 | – |
| 02.10.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 599.803,73 USD | 303,54 USD | 1.976 | – |
| 02.10.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 251.991,41 USD | 302,51 USD | 833 | – |
| 03.09.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 115.591,68 USD | 288,98 USD | 400 | – |
| 03.09.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 110.697,24 USD | 287,53 USD | 385 | – |
| 03.09.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 605.649,07 USD | 286,36 USD | 2.115 | – |
| 03.09.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 513.300,78 USD | 285,17 USD | 1.800 | – |
| 03.09.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 85.195,62 USD | 283,99 USD | 300 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 119.763,01 USD | 292,82 USD | 409 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 289.086,49 USD | 291,71 USD | 991 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 58.120,00 USD | 290,60 USD | 200 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 145.770,51 USD | 289,80 USD | 503 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 102.794,86 USD | 288,75 USD | 356 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 349.356,54 USD | 287,77 USD | 1.214 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 295.974,30 USD | 286,80 USD | 1.032 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 44.860,50 USD | 285,74 USD | 157 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 9.390,25 USD | 284,55 USD | 33 | – |
| 03.08.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 29.834,44 USD | 284,14 USD | 105 | – |
| 01.07.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 190.291,02 USD | 317,15 USD | 600 | – |
| 01.07.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 284.199,75 USD | 315,78 USD | 900 | – |
| 01.07.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 31.457,88 USD | 314,58 USD | 100 | – |
| 01.07.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 219.420,18 USD | 313,46 USD | 700 | – |
| 01.07.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 337.572,95 USD | 312,28 USD | 1.081 | – |
| 01.07.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 348.814,68 USD | 311,72 USD | 1.119 | – |
| 01.07.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 32.261,04 USD | 310,20 USD | 104 | – |
| 01.07.2026 |
Ligand Pharmaceuticals Inc.
CLO & Secretary
|
CLO & Secretary | Verkauf | 122.359,49 USD | 308,99 USD | 396 | – |
Alle von „Reardon Andrew" gemeldeten Eigengeschäfte (Directors' Dealings) gemäß Art. 19 MAR bzw. den jeweiligen nationalen Pflichtmeldungen. Gleiche Personen können unter abweichenden Schreibweisen mehrfach geführt sein. „Seit Meldung" vergleicht den aktuellen Kurs (deutsche Handelsplätze, EUR) mit dem gemeldeten EUR-Preis der Transaktion — Meldungen in anderen Währungen bleiben ohne Angabe. Details in der Methodik.